How to buy Travere Therapeutics stock | 24.11

Travere Therapeutics, Inc is a biotechnology business based in the US. Travere Therapeutics shares (RTRX) are listed on the NASDAQ and all prices are listed in US Dollars. Travere Therapeutics employs 221 staff and has a trailing 12-month revenue of around USD$194 million.

How to buy shares in Travere Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Travere Therapeutics. Find the stock by name or ticker symbol: RTRX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Travere Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$24.11, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Travere Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Travere Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Travere Therapeutics's share price?

Since the stock market crash in March caused by coronavirus, Travere Therapeutics's share price has had significant positive movement.

Its last market close was USD$24.11, which is 28.33% up on its pre-crash value of USD$17.28 and 168.49% up on the lowest point reached during the March crash when the shares fell as low as USD$8.98.

If you had bought USD$1,000 worth of Travere Therapeutics shares at the start of February 2020, those shares would have been worth USD$690.78 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,543.52.

Travere Therapeutics share price

Use our graph to track the performance of RTRX stocks over time.

Travere Therapeutics shares at a glance

• Key figures

Information last updated 2020-11-19.

Latest market close	USD$24.11
52-week range	USD$8.98 - USD$24.96
50-day moving average	USD$21.3801
200-day moving average	USD$19.0224
Wall St. target price	USD$31.38
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-3.417

Buy Travere Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy Travere Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Travere Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Travere Therapeutics price performance over time

Historical closes compared with the close of $24.11 from 2020-11-16

1 week (2020-11-13)	1.82%
1 month (2020-10-22)	14.37%
3 months (2020-08-21)	30.11%
6 months (2020-05-22)	44.72%

1 year (2019-11-22)	76.24%
2 years (2018-11-21)	-6.62%
3 years (2017-11-22)	12.56%
5 years (2015-11-20)	24.09%

Travere Therapeutics financials

Revenue TTM	USD$194 million
Gross profit TTM	USD$170.1 million
Return on assets TTM	-6.61%
Return on equity TTM	-28.53%
Profit margin	-40.24%
Book value	$5.907
Market capitalisation	USD$1.2 billion

TTM: trailing 12 months

Shorting Travere Therapeutics shares

There are currently 4.8 million Travere Therapeutics shares held short by investors – that's known as Travere Therapeutics's "short interest". This figure is 1.6% up from 4.7 million last month.

There are a few different ways that this level of interest in shorting Travere Therapeutics shares can be evaluated.

Travere Therapeutics's "short interest ratio" (SIR)

Travere Therapeutics's "short interest ratio" (SIR) is the quantity of Travere Therapeutics shares currently shorted divided by the average quantity of Travere Therapeutics shares traded daily (recently around 265521.38121547). Travere Therapeutics's SIR currently stands at 18.1. In other words for every 100,000 Travere Therapeutics shares traded daily on the market, roughly 18100 shares are currently held short.

However Travere Therapeutics's short interest can also be evaluated against the total number of Travere Therapeutics shares, or, against the total number of tradable Travere Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Travere Therapeutics's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Travere Therapeutics shares in existence, roughly 90 shares are currently held short) or 0.104% of the tradable shares (for every 100,000 tradable Travere Therapeutics shares, roughly 104 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Travere Therapeutics.

Find out more about how you can short Travere Therapeutics stock.

Travere Therapeutics share dividends

We're not expecting Travere Therapeutics to pay a dividend over the next 12 months.

Have Travere Therapeutics's shares ever split?

Travere Therapeutics's shares were split on a 1:9 basis on 8 November 2011. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Travere Therapeutics shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Travere Therapeutics shares which in turn could have impacted Travere Therapeutics's share price.

Travere Therapeutics share price volatility

Over the last 12 months, Travere Therapeutics's shares have ranged in value from as little as $8.98 up to $24.96. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Travere Therapeutics's is 0.721. This would suggest that Travere Therapeutics's shares are less volatile than average (for this exchange).

Travere Therapeutics overview

Retrophin, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences, NGLY1.org, and Alagille Syndrome Alliance for identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.

Frequently asked questions

• What percentage of Travere Therapeutics is owned by insiders or institutions?

  Currently 0.895% of Travere Therapeutics shares are held by insiders and 104.799% by institutions.

• How many people work for Travere Therapeutics?

  Latest data suggests 221 work at Travere Therapeutics.

• When does the fiscal year end for Travere Therapeutics?

  Travere Therapeutics's fiscal year ends in December.

• Where is Travere Therapeutics based?

  Travere Therapeutics's address is: 3721 Valley Centre Drive, San Diego, CA, United States, 92130

• What is Travere Therapeutics's ISIN number?

  Travere Therapeutics's international securities identification number is: US7612991064

• What is Travere Therapeutics's CUSIP number?

  Travere Therapeutics's Committee on Uniform Securities Identification Procedures number is: 250392305